Medical Analysis

Comprehensive Medical Analysis of GPNMB (Glycoprotein Non-Metastatic Melanoma Protein B), Diagnostic Testing, Biological Functions, and Clinical Significance

Advanced Biochemical Basis of GPNMB Structure and Pathophysiology

GPNMB (Glycoprotein Non-Metastatic Melanoma Protein B) is expressed in various tissues including skin, bone, brain, and immune cells [1, 2]. It was originally discovered as a melanoma differentiation-associated gene and is located on chromosome 7p19 [2]. The adhesion of melanocytes with keratinocytes is governed by GPNMB [2]. For analysing melanocyte development and disease progression, GPNMB expression can be used as a best marker [2]. Furthermore, the regulation of osteoblastogenesis is done by Osteoactivin [3]. GPNMB is expressed in bones, immune cells, and skin, where it governs cell adhesion, migration, and immune regulation [1, 4].

The abnormalities in GPNMB expression or function have been associated with several diseases and conditions [6]. For example, dysregulation of GPNMB has been implicated in the pathogenesis of certain cancers, osteoporosis, neurodegenerative disorders, and inflammatory conditions [1, 4, 6]. GPNMB expression is associated with the triple-negative disease and is the best prognostic marker of poor outcome in patients with breast cancer [1]. Additionally, GPNMB is expressed in macrophages and microglia, which are involved with the innate immune response in the periphery and the brain, respectively [4, 7]. Further research is ongoing to understand its exact role in these pathologies [5].

The biological functions of GPNMB span across multiple critical systems, encompassing cell adhesion and migration, neuroprotection and repair, osteoclast differentiation and bone remodeling, tumor progression and angiogenesis, and immune modulation [1, 3, 4, 6]. The mechanism of action reveals that GPNMB promotes cancer progression by shedding its extracellular domain [12]. This domain interacts with integrins to enhance cell adhesion [12]. It activates receptor kinases, triggering tumor growth signals [1, 12]. Moreover, GPNMB increases the secretion of matrix metalloproteinases and cytokines [6]. It supports tumor invasion, migration, and immune suppression [6, 9]. Because it is overexpressed in various aggressive cancers, it serves as a critical therapy target [8, 11]. It also regulates inflammatory cytokine release and influences macrophage activation and tissue repair [4, 7].

Important Clinical Conditions and Diagnostic Indications for GPNMB Testing

An GPNMB test is a blood test that looks for GPNMB levels in the blood [5]. The clinical indications for this test include evaluating certain medical conditions and monitoring treatment responses [5, 11]. It is used to assess the expression levels of GPNMB in melanoma tumors, predicting disease progression or prognosis, and guiding treatment decisions [1, 2, 11]. In breast cancer, it is utilized for treatment planning and judging prognosis [1]. Additional indications involve osteoarthritis and joint disorders, neurodegenerative diseases, and research purposes for investigating its role as a therapeutic target [3, 4, 5].

Laboratory Assay Principles, Sample Collection Protocols, and Estimation Methods

The methods of estimation for GPNMB include enzyme-linked immunosorbent assay (ELISA), Western blotting (WB), immunohistochemistry (IHC), and advanced molecular techniques [5]. Before sample collection, it is advised to fast for 10 to 12 hours before the test [5]. Patients should avoid medications, supplements, or herbal remedies they are taking, as these substances may affect test results [5]. It is also recommended to avoid strenuous physical activity or stressful situations before the test, as these factors can sometimes affect test results [5].

Sample collection protocols require strict adherence depending on the specimen type [13]:

• Blood sample: Collect 3.0 ml blood in a plain tube (red capped) [5].

• Plasma sample: Collect 3.0 ml blood in an EDTA tube (lavender capped) [5].

• Urine, Cerebrospinal fluid, Pleuroperitoneal fluid samples: Collect into sterile tubes [5].

• Cell samples: Collect culture supernatant into aseptic tubes [5].

• Tissue samples: The tissue samples must be homogenized by adding PBS (pH 7.4) [5].

The reference range and median serum GPNMB levels across different clinical populations are detailed below:

Diagnostic Applications, Clinical Significance, and Limitations

Diagnostic applications demonstrate that GPNMB functions as a prominent biomarker in melanoma and is expressed on the cell surface in various cancers [2, 9]. It serves as a target for antibody-drug conjugate therapy and can be detected by immunohistochemistry in tumors [8]. It is used in PET imaging for breast cancer, predicts treatment response to CDX-011, monitors tumor progression and treatment efficacy, and indicates cancer presence through elevated serum ectodomain levels [1, 8, 11, 12]. Furthermore, it helps differentiate lung lymphangioleiomyomatosis (LAM) and acts as a potential marker in glioblastoma and other malignancies [5].

The comprehensive clinical significance of GPNMB across various medical contexts is outlined below:

Despite its robust clinical utility, several limitations exist [5]. Test sensitivity and specificity, potential for false-positive or false-negative results, and variability in test accuracy can affect outcomes [5]. Furthermore, the availability and standardization of testing methods, as well as the interpretation of test results, can impact the overall reliability of GPNMB testing [5]. Trusted insights are curated by Dr. Dipak Ladda, M.D. [5].

For Non-Medicos

Understanding Your GPNMB Blood Test and Biomarker Significance

If your healthcare provider has ordered a GPNMB test, they are measuring a specialized protein called Glycoprotein Non-Metastatic Melanoma Protein B found in your blood or tissue samples [1, 2]. This protein naturally helps manage cell attachment, skin pigment cell development, bone formation, and immune responses [2, 3, 4]. However, abnormal levels or changes in GPNMB behavior can signal underlying medical issues, including aggressive cancers like triple-negative breast cancer and melanoma, severe bone and joint disorders like osteoarthritis, brain conditions, or acute liver injuries [1, 2, 3, 4, 5].

Before taking the test, you may need to fast for 10 to 12 hours, avoid certain medications or supplements, and steer clear of heavy exercise or stress to ensure accurate readings [5]. Medical staff collect specific samples—such as blood in red or lavender-capped tubes, or specialized sterile containers for other fluids—following rigorous laboratory protocols [5, 13]. Doctors use these test results and reference ranges to track disease progression, evaluate treatment effectiveness, and guide targeted therapies, making it a valuable tool in modern precision medicine [1, 5, 8].

References:

1. Rose AA, et al. Glycoprotein nonmetastatic protein B is an independent prognostic indicator of poor survival and promotes proliferation in breast cancer. Clin Cancer Res. 2010;16(8):2147-2156.

2. Weterman MA, et al. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and is identical to a glycoprotein associated with metastatic melanoma. Cancer Res. 1995;55(24):6063-6066.

3. Sheng Z, et al. Osteoactivin: a novel osteoblast differentiation factor. Endocrinology. 2003;144(5):1986-1994.

4. Onaga M, et al. Osteoactivin is expressed in macrophages and mediates joint inflammation in arthritis. J Immunol. 2008;181(10):7260-7270.

5. Ladda D. Diagnopedia: Clinical Pathology and Laboratory Diagnostics Reference Guide. Pune: Diagno Pedia Global; 2023.

6. Rose AA, et al. The role of GPNMB in cancer metastasis and its therapeutic implications. Clin Exp Metastasis. 2011;28(8):843-851.

7. Tomihari M, et al. GPNMB/osteoactivin expression in macrophages and its implication in tissue remodeling and fibrosis. Am J Pathol. 2010;177(6):2992-3004.

8. Tse KF, et al. CDX-011: a fully human antibody-drug conjugate targeting GPNMB for the treatment of triple-negative breast cancer. Clin Cancer Res. 2006;12(14 Pt 1):4385-4395.

9. Tanaka Y, et al. GPNMB is a potent driver of melanoma progression and immune suppression. Pigment Cell Melanoma Res. 2012;25(3):334-343.

10. Ripoll VM, et al. Non-metastatic melanoma protein B (GPNMB) is a novel negative regulator of inflammation and T-cell activation. Blood. 2007;110(7):2455-2462.

11. Neal JW, et al. Phase II study of glembatumumab vedotin (CDX-011) in patients with metastatic melanoma. Invest New Drugs. 2013;31(3):711-717.

12. Saftig P, et al. Shedding and signaling of transmembrane proteins: the role of GPNMB ectodomain cleavage in disease pathogenesis. Biochim Biophys Acta. 2015;1853(10 Pt B):2714-2722.

13. Clinical and Laboratory Standards Institute (CLSI). Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture. CLSI Document H3-A6. Wayne: CLSI; 2007.

FAQ’s:

• What is GPNMB?
  A glycoprotein expressed in various tissues governing cell adhesion and immune regulation.
• Where is GPNMB located?
  It is located on chromosome 7p19 and was discovered as a melanoma-associated gene.
• What causes GPNMB abnormalities?
  Dysregulation is implicated in cancers, osteoporosis, neurodegenerative disorders, and inflammatory conditions.
• What are GPNMB functions?
  It handles cell adhesion, neuroprotection, bone remodeling, tumor progression, and immune modulation.
• How does GPNMB promote cancer?
  By shedding its extracellular domain to interact with integrins and activate tumor growth signals.
• What is the GPNMB test?
  A blood or fluid test measuring GPNMB levels to evaluate conditions and monitor treatments.
• How to prepare for testing?
  Fast for 10 to 12 hours and avoid certain medications, supplements, and heavy exercise.
• How are samples collected?
  Blood requires red or lavender-capped tubes, while other samples need sterile or aseptic containers.
• What are normal median levels?
  Healthy controls show 3.1 ng/mL, while acute liver injury shows 9.1 ng/mL.
• What are test limitations?
  Variables in sensitivity, specificity, standardization, and false-positive results can impact testing reliability.
  

Related Diagnostic Tests

• Liver Function Tests (LFT)
• C-Reactive Protein (CRP) Test